Whalesbook
Financial Highlights for FY26
RPG Life Sciences announced its audited financial results for the fiscal year and quarter ending March 31, 2026.
The company reported consolidated revenue of ₹707.52 crore for FY26, with a Profit After Tax (PAT) of ₹115.17 crore.
For the fourth quarter of FY26, revenue stood at ₹176.89 crore, and PAT was ₹29.98 crore.
The Board of Directors has recommended a final dividend of ₹24 per equity share for FY2025-26, subject to shareholder approval.
The board also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a five-year term.
RPG Life Sciences also approved amendments to its Code of fair disclosure and updated its trading window policy.
Key Implications of the Results
The proposed ₹24 per equity share dividend directly rewards shareholders, reflecting the company's profitability.
Dr. Samdani's appointment as an independent director is intended to strengthen board oversight and corporate governance.
However, a key point from the auditor's report flags a 'going concern' risk, which raises questions about the company's long-term financial sustainability.
The company is also monitoring the finalisation of rules and clarifications for new Labour Codes, which may carry accounting implications.
Company Overview and Historical Performance
RPG Life Sciences, part of the RPG Group, operates in the pharmaceutical sector, manufacturing and marketing pharma products and APIs, with presence in India and exports.
The company has shown growth, with FY25 revenue at ₹634 crore and PAT at ₹80 crore, up from FY24 revenue of ₹590 crore and PAT at ₹73 crore.
Last fiscal year, FY2023-24, the company recommended a final dividend of ₹15 per equity share.
The auditor's 'going concern' note has appeared in previous years' reports, indicating this is a persistent risk the company has been managing.
Immediate Outlook and Shareholder Focus
Shareholders will await formal approval of the ₹24 per share dividend at the upcoming Annual General Meeting (AGM).
The board composition is strengthened by the new independent director, potentially leading to enhanced strategic guidance.
Management will need to address the auditor's 'going concern' observation and outline clear strategies for long-term financial stability.
Updates on the finalisation and accounting impact of the new Labour Codes will also be closely watched.
Key Risks and Challenges
The persistent 'going concern' qualification from the auditor remains a key risk, signaling underlying financial challenges that need a robust resolution for the company's long-term viability.
Uncertainty regarding the final rules and accounting treatments for the new Labour Codes could present compliance and financial reporting challenges.
Industry Peer Comparison
RPG Life Sciences operates in the same pharmaceutical landscape as major players like Torrent Pharmaceuticals, Lupin, and Cipla.
However, RPG Life Sciences is a considerably smaller entity compared to these large-cap peers, which reported FY26 revenues ranging from approximately ₹10,700 Cr to ₹18,400 Cr.
Despite its smaller size, RPG Life Sciences achieved strong PAT growth in FY26 and proposed a significantly higher dividend than last year.
Next Steps and Investor Watchlist
Shareholder vote outcome on the proposed final dividend at the AGM.
Management's commentary and action plan concerning the 'going concern' risk flagged by auditors.
The final rules for the new Labour Codes and their specific impact on operational costs and financial statements.
Performance trends in upcoming quarters to assess sustained growth and how risks are being addressed.